Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG (CRSP) Stock Price & Analysis


CRSP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$38.94 - $86.95
Previous Close$55.27
Average Volume (3M)1.09M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$1.90B
Total Debt (Recent Filing)$242.16M
Price to Earnings (P/E)-6.3
Next EarningsFeb 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-8.80
Shares Outstanding78,294,139
Standard Deviation0.19
10 Day Avg. Volume926,692
30 Day Avg. Volume1,085,466
Price to Book (P/B)2.04
Price to Sales (P/S)9528.22
Price to Cash Flow (P/CF)13.10
P/FCF Ratio-9.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside65.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $38.94 and its highest was $86.95 in the past 12 months.
    What is Crispr Therapeutics AG’s market cap?
    Currently, no data Available
    When is Crispr Therapeutics AG’s upcoming earnings report date?
    Crispr Therapeutics AG’s upcoming earnings report date is Feb 14, 2023 which is in 8 days.
      How were Crispr Therapeutics AG’s earnings last quarter?
      Crispr Therapeutics AG released its earnings results on Nov 01, 2022. The company reported -$2.24 earnings per share for the quarter, beating the consensus estimate of -$2.278 by $0.038.
        Is Crispr Therapeutics AG overvalued?
        According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Crispr Therapeutics AG pay dividends?
          Crispr Therapeutics AG does not currently pay dividends.
          What is Crispr Therapeutics AG’s EPS estimate?
          Crispr Therapeutics AG’s EPS estimate is -$2.29.
            How many shares outstanding does Crispr Therapeutics AG have?
            Crispr Therapeutics AG has 78,294,136 shares outstanding.
              What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
              Crispr Therapeutics AG reported an EPS of -$2.24 in its last earnings report, beating expectations of -$2.278. Following the earnings report the stock price went up 5.113%.
                Which hedge fund is a major shareholder of Crispr Therapeutics AG?
                Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 538M.


                  Crispr Therapeutics AG Stock Smart Score

                  The Crispr Therapeutics AG stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Crispr Therapeutics AG

                  CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  MoonLake Immunotherapeutics
                  VectivBio Holding
                  ADC Therapeutics
                  AC Immune SA

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis